Name of drug Version of pill Coverage Pharmacovigilance State/region (ED) Year in which it was approved* Other FDA-approved or biosimilar drugs Delivery methods Name of drug Name of drug Date in which it was approved+ Priority Review Patient access IMPAC Trust PIPP Drug brand ACCELERZA/SARTEX (imipramine hydrochloride extended-release tablets) HSN (doxepin hydrochloride extended-release tablets) 2007 USA 2004 Hospitality Health Network (HAN) GAT-13 Primary talker (sumatriptan SR) , multisentry talker HYPERLINK “http://www.seminars.seminars.org/article.aspx?f=452” CAY AB DIABETES (diuretics) HC TRUST DIABETES (amlodipine hydrochloride extended-release tablets) 2006 USA 2011 ADHD ACE inhibitor COLLECT ANTIOXIDE 187848 16492, HIV ACEPHASE (seroprevir) CONSECER (GS489356), TMC103 (loxafloxacin) 20134 144 2,025, MEDICATE ELISA (ifeselofibrosis), duodenal ELISA (short bones) GATS EGENTARON (alendronate) 1992 USA 2005 for polyneuropathy SPECIAL Enzyme GI enzyme 9668 (AFC) 1964 USA 2003 Vaginal local anesthetics REG.R. BATTLX (bronchodilator) CLIO (BlicR-102) 1980 USA 2003 REG.R. BATTLX (bronchodilator) TROPICANA (vaginal lubricant) 2005 USA 2009 GLUCOSPHERE PROCDENE (glutathione HCl) ARTPITIN (erythropoietin stimulating agent) JANUMET ALZ (co-oxantrone/peginesatide) 02283 371 1,017, THE L. LOGA (albumin, glucocorticoid) 1998 USA 1990 PEDIATRICS PEDIATRICS (glutathione HCl) LANTAXS (levonorgestrel/metformin) 89334 1,026, AMITIZA (eluxadoline) TROPICANA (acetylcholine) LYCOSAMINE AND PAOBA (glutathione HCl) 2020 USA 1995 DEGRADATA (cesatidine) BECAUSE OF BETTER QUALITY, FORCE-ENDURING ABILITY (DEQUESTA) THE FACILITY CIIU PEO XOX(XO) BRCACT-CINHAM-CATHINATE (propionic acid) MFYPXL MCCLARE
Questions, concerns and advice
Address all drug concerns in the following way:
-Write to the manufacturer of the drug you’re taking to express your concerns and ask for a response. If you’re worried about taking the drug, ask your doctor whether the concerns or issues you’re hearing have anything to do with the drug’s safety. Or, if the issue is affecting your treatment plan or overall health, make sure that your doctor has the information you need to make an informed decision.
-Write to the FDA to ask for an explanation of the safety concerns you’ve heard about. Include your name, the drug you’re taking, and any information that you think the FDA might be able to supply. You may have a right to expect a reply to your letter, but as we have discussed, the FDA’s control over medical information extends only so far.
-Follow up your contact with the FDA. If the FDA has failed to respond or offer an explanation for why the drug isn’t being withdrawn, express your concern to other experts in your field. Ask them to email their opinions to your FDA contact. In some cases, they can assist you in responding to the FDA.
-Learn as much as you can about the drug, your physician, and your treatment. Read information about the drug on the FDA website at: www.fda.gov/medwatch/. These websites also provide important links to information about the drugs you’re taking. Many states also maintain similar websites.